LEASE AGREEMENT By and Between SKS HARBOR BAY ASSOCIATES, LLC, a Delaware limited liability company (“Landlord”) and BIOTIME, INC., a California corporation (“Tenant”) October 28, 2010Lease Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances) • California
STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances) • California
This Agreement is entered into by Life Extension Foundation (“Purchaser”) and Embryome Sciences, Inc., a California corporation (the “Company).
Between ES Cell International Pte Ltd.Shareholders Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances)
THIS AMENDED AND RESTATED SHAREHOLDERS AGREEMENT (the “Agreement”) is signed on this 7th day of October 2010 subject to the Effective Date (defined below).
ContractMerger Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances) • California
AMENDED AND RESTATED RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances)
This Amended and Restated Research and License Agreement (this “Amendment”) is made and entered into as of the Date of Amendment (as defined herein), as an amendment of the Research and License Agreement signed between the Parties on the Effective Date (the “Original Agreement”, and, as amended by this Amendment, the “Agreement”), by and between: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., a company duly incorporated under the laws of Israel (“Hadasit”) and CELL CURE NEUROSCIENCES LTD., a company duly incorporated under the laws of Israel (the “Company”) (each a “Party” and jointly the “Parties”).
CO-EXCLUSIVE SUPPLY AGREEMENTCo-Exclusive Supply Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances) • Hong Kong
THIS EXCLUSIVE SUPPLY AGREEMENT (the “Agreement”) is made as of December 8, 2010 (the “Effective Date”), by and between BioTime Asia, Limited, a Hong Kong company and subsidiary of BioTime, Inc., with a registered office at 3/F, Gloucester Tower, The Landmark, 15 Queen’s Road Central, Central, Hong Kong (“BTA”), and Shanghai Genext Medical Technology Co. Ltd, a Chinese company with its principal address at Bldg 10, 3 C2, Pujiang Intelligence Valley, 1188 Lianhang Road, Shanghai 201112, P.R. China (“Genext”).
ADDITIONAL RESEARCH AGREEMENTAdditional Research Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances)
This Additional Research Agreement (this "Agreement"), by and between Hadasit Medical Research Services and Development Ltd., a company duly incorporated under the laws of Israel (“Hadasit”) and Cell Cure Neurosciences Ltd., a company duly incorporated under the laws of Israel (the “Company”), is entered into and is effective subject to and as of the going into force of the Amended License Agreement (as defined below) (the "Effective Date").
EXCLUSIVE LICENSE AGREEMENT between Cell Targeting, Inc. and Burnham Institute for Medical ResearchExclusive License Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances) • California
This Exclusive License Agreement (“Agreement”), is entered into as of the 20th day of November, 2007 (hereinafter called “Effective Date”), by and between the Burnham Institute for Medical Research (the “Institute”), a California 501(c)(3) corporation, having its principal place of business at 10901 North Torrey Pines Road, La Jolla, CA 92037, and Cell Targeting, Inc. (“Licensee”), a Delaware corporation, having its principal place of business at 11000 Cedar Avenue, Suite 100, Cleveland, OH, 44106.
RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENTResearch and Exclusive License Option Agreement • March 15th, 2011 • Biotime Inc • Biological products, (no disgnostic substances)
THIS AGREEMENT is made on October 7, 2010 effective subject to the closing of the investment round envisaged in the Share Purchase Agreement (as defined herein) (the date being of such closing being referred to herein as the "Effective Date") between
